Could a diabetes drug tame PCOS inflammation better than standard care?
NCT ID NCT05966792
First seen Apr 30, 2026 · Last updated May 01, 2026 · Updated 1 time
Summary
This study looked at whether a newer diabetes drug, called an SGLT2 inhibitor, can improve symptoms of Polycystic Ovary Syndrome (PCOS) better than the standard medicine metformin. PCOS involves chronic inflammation, and the drug may work by reducing that inflammation. The trial included 82 women aged 18-45 with PCOS and a BMI of 20 or higher.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYSTIC OVARY SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Tenth People'S Hospital
Shanghai, Shanghai Municipality, 200072, China
Conditions
Explore the condition pages connected to this study.